Featured - 4 items
Transforming pharmaceutical R&D with PwC
The pharmaceutical industry is evolving at a rapid pace that has a direct impact on R&D organizations:
- Fundamental shift into novel drug modalities (CAR-T, mRNA, gene therapy) impacting R&D functional needs
- Trial designs that are increasingly complex but require a tradeoff between scientific rigor and operational feasibility
- A need for a patient-centric clinical trial model that improves access beyond the traditional 2% of the US
- Cost pressures on operations that are ripe for technology innovation
- Evidence generation and its impact among regulatory bodies, payers, and other key pharma customers continues to evolve rapidly
To address these challenges, our team delivers innovative solutions that streamline R&D, accelerate market entry by operationalizing new scientific modalities and enhance decision-making through AI and automation.
What challenges can we help you solve?
- Intelligent clinical trials (ICT)
- R&D portfolio decision analytics
- Medical Affairs transformation
- R&D regulatory operations
- R&D deals and innovation
- Provider and retail-led clinical trials
- R&D clinical development excellence
Intelligent clinical trials (ICT)
Clinical trials are increasingly complex and resource-intensive, often resulting in extended timelines, high costs, and delayed delivery of therapies to patients, posing a significant challenge to the industry.
We leverage a suite of integrated clinical trial design accelerators that reduce resources required, accelerate cycle timelines, reduce trial costs and improve protocol execution efficiency and success rate.
R&D portfolio decision analytics
Pharmaceutical companies struggle to balance the continuous evolution of their R&D operations against the backdrop of lengthy, costly, and laborious implementations, necessitating a standard for integrating operational data to streamline insights and reduce organizational burden.
We work with you to transform your ways of working by bringing proven expertise in R&D PPM capabilities coupled with a technology enabled execution approach that helps our clients answer business critical questions about their portfolio.
Medical Affairs transformation
Medical Affairs teams face obstacles in adopting new approaches and technologies to generate value for patients, cross-functional partners, and customers within an ever-changing and complex healthcare environment.
We work with Medical Affairs leadership to drive transformation and capability development to enhance the value of medical, leveraging innovative technologies and establishing improved operating models.
R&D regulatory operations
Regulatory organizations face the challenge of efficiently managing correspondence and engagement with health authorities, while upholding global quality and compliance, which is crucial for regulatory executives.
We support the evolution of R&D Global Regulatory Affairs organizations by incorporating disruptive technologies and new ways of working to reduce submissions cycle times, to strengthen Health Authority relationships, and to improve the probability of regulatory success.
R&D deals and innovation
Organizations must find ways to enable external innovation and expedite asset development programs by leveraging medical insights accelerators to effectively drive strategic decisions impacting clinical development and real-world evidence programs.
We enable R&D leaders to extract maximum deal value and growth through an asset-led approach to transactions, allowing functional teams to focus on what they do best — science. We also help to reduce the operational burden of transaction planning and prioritize safe, effective study cutovers, while protecting patient / regulatory outcomes.
Provider and retail-led clinical trials
PwC leveraged its experience in clinical operations to develop alternative delivery models, such as retail, during the COVID-19 pandemic. As these models evolved, PwC has taken the lead in creating an enterprise-grade clinical research platform for top Academic Medical Centers (AMCs) and large-scale provider networks, focusing on both sponsor and patient-centricity at scale.
We help architect, build, and connect provider networks to create an integrated, end-to-end support model. This approach enables organizations to run more sophisticated clinical trials and offers their patient populations greater access to innovative care.
R&D clinical development excellence
The challenge lies in lowering drug development costs, enhancing patient and site experiences, and accelerating cycle times through optimized clinical trial planning and execution, supported by operating model efficiencies, process optimization, and AI and automation.
We transform clinical development of biopharmaceutical products by optimizing the patient experience, digitalizing and streamlining operations, and ensuring regulatory compliance to efficiently bring innovative therapeutic solutions to market.
Why PwC?
Deep functional knowledge in pharmaceutical and life sciences
We pair deep functional knowledge and experience working across the pharmaceutical and life sciences value chain with robust technical capabilities.
Business outcome focused, technology powered
We start with the business outcome you’re after — or the challenge you’re facing — and holistically develop a solution, powered by technology to get you there faster.
Goal-oriented AI
We reinforce our R&D expertise with a suite of tech-empowered accelerators, strategic alliances, and significant investments in Generative AI, ensuring you leverage the best-in-class technology advancements.
PwC’s strategic alliances in R&D
Contact us
